Solitary pulmonary nodule evaluation of solitary pulmonary nodule
|
Pulmonary Nodule Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Solitary pulmonary nodule evaluation of solitary pulmonary nodule On the Web |
|
American Roentgen Ray Society Images of Solitary pulmonary nodule evaluation of solitary pulmonary nodule |
|
FDA on Solitary pulmonary nodule evaluation of solitary pulmonary nodule |
|
CDC on Solitary pulmonary nodule evaluation of solitary pulmonary nodule |
|
Solitary pulmonary nodule evaluation of solitary pulmonary nodule in the news |
|
Blogs on Solitary pulmonary nodule evaluation of solitary pulmonary nodule |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Maria Fernanda Villarreal, M.D. [2]
Overview
A hallmark feature in the evaluation of solitary pulmonary nodule is the malignancy risk assessment. The evaluation approach of solitary pulmonary nodule will mainly depend in the initial morphological evaluation of the nodule (size, margins, contours, and growth). Other characteristics, such as: location, clinical features, and distribution may be helpful for the risk assessment, therapeutical management, surveillance, and follow-up of solitary pulmonary nodule. Solitary pulmonary nodule can be divided into 4 risk categories: low risk, intermediate, moderate and high risk. Based upon these risk categories, complementary diagnostic studies and management, include: PET/CT scan, CT scan, non-surgical biopsy, and surgical resection.
Evaluation of Solitary Pulmonary Nodule
Initial Evaluation Algorithm
Solitary Pulmonary Nodule Detected | |||||||||||||||||||||||||||||||||
Step 1: Assess likelihood of cancer ❑ Mayo Clinic Malignancy Risk Calculator | |||||||||||||||||||||||||||||||||
| Step 2: Review prior films Is there a growth? | No previous films *Refer to step 2A | ||||||||||||||||||||||||||||||||
| Yes, growing | No, stable | ||||||||||||||||||||||||||||||||
Step 2A Enhanced Computed Tomography | Step 2B Surveillance | ||||||||||||||||||||||||||||||||
Location ❑ Upper lobe ❑ Lower lobe ❑ Middle lobe Size ❑ < 8mm ❑ > 8mm Lesion characteristics ❑ Margins (irregular/regular) ❑ Shape (spiculated/rounded) ❑ Attenuation | |||||||||||||||||||||||||||||||||
Other Diagnostic Studies ❑ PET/CT scan | |||||||||||||||||||||||||||||||||
| Low risk ❑ < 5% | Intermediate risk ❑ 5-65% | High risk ❑ > 65% | |||||||||||||||||||||||||||||||
| Serial CT scans | Non-surgical biopsy *Refer to Step 3: Treatment and Follow-up | Surgical resection *Refer to Step 3: Treatment and Follow-up | |||||||||||||||||||||||||||||||
Step 3: Treatment and Follow-up | |||||||||||||||||||||||||||||||||
Malignancy Risk Assessment
The malignancy risk assessment for pulmonary nodule considers the following factors:[1]
- Age
- Smoking
- Current
- Never smoker
- Cancer
- Extrathoracic cancer more than 5 years prior
- Nodule diameter
- Spiculation
- Yes
- No
- Upper lobe
- Yes
- No
- The risk calculator is not validated for patients with history of cancer in the past 5 years.[1]
The malignancy of pulmonary nodule, can be categorized into 3 groups:
Low probability
- Usually less than <5 percent
- The nodule size is less than or equal to 4 mm
- The nodule size is between 4-6 mm
- Observation is suggested
- Observation usually involves radiologic surveillance with serial CT scans.
Read More: http://www.atsjournals.org/doi/full/10.1164/rccm.201104-0679CI#.VvAbTxjf5mo
Intermediate probability
- Between 5 to 65 percent
- The nodule size is between 6-8 mm and associated risk factors
- Diagnostic testing is indicated: positron emission tomography (PET), CT-FNA, and bronchoscopy
High probability
- More than >65 percent
- Follow similar management algorithm for lung cancer.
The patient risk assessment of pulmonary nodule, can be categorized into 2 groups:
- High risk patients
- Patient age is > 35
- Positive smoking history
- Male patients
- Positive for prior malignancy
- Other associated risk factors.
- Low risk patients
- Patient age < 35
- Smoking history:
- No smoking history
- Female patients
- Negative for prior malignancy
- No associated risk factors